Expert interviews

Giancarlo Comi comments on the SUNBEAM and RADIANCE trial findings looking at the effects of ozanimod versus interferon beta-1α on brain volume loss in relapsing multiple sclerosis (1:50).

Danielle Bastiaansen outlines the red flags to identifying automimmune encephalitis to prevent misdiagnosis of dementia syndromes (5:44).

Ermelinda De Meo outlines research suggesting multiple sclerosis in young patients not only has an impact on grey matter degeneration, but also cortical development trajectories (1:26).

Giancarlo Comi discusses the outcomes of the TOPAZ study showing sustained efficacy of alemtuzumab on clinical and magnetic resonance imaging outcomes through 8 years in patients with relapsing─remitting multiple sclerosis (1:56).

Gavin Giovannoni provides his thoughts on ocrelizumab’s sustained effect on disability progression risk reduction in multiple sclerosis patients based on a 5-year follow-up of pooled data from the OPERA I and II trials (4:19).

José Antonio Monge-Argilés describes his study showing how alpha-synuclein levels can improve early differential diagnosis between progressive dementia types (3:13).

Nina Grytten discusses research suggesting a need for increased awareness of cancer risk in patients with multiple sclerosis to improve outcomes and survival (2:46).

Oliver Cousins summarizes his research highlighting semantic fluency impairment and underlying amygdala atrophy as predictive factors of cognitive decline in patients with Parkinson’s disease (3:58).

Sara Garcia-Ptacek summarizes findings suggesting that an Alzheimer’s disease diagnosis should not necessarily prevent individuals from receiving statins (2:29).

Tayyabah Yousaf reports on findings that glucocerebrosidase gene mutations are associated with structural cerebral abnormalities even in the absence of clinical manifestations of Parkinson’s disease (2:38).

Jonathan Santoro summarises their research evaluating disability distribution in paediatric-onset multiple sclerosis using a novel scoring model, and discusses the implications for the care of patients (4:31).

Laurent Servais presents the safety and exploratory efficacy data from the SUNFISH study evaluating the SMN2 pre‐mRNA splicing modifier risdiplam in individuals who have type 2 or 3 spinal muscular atrophy (4.33).

Jens Kuhle discusses their analysis of data from the EXPAND trial indicating that blood neurofilament light chain levels could be a biomarker for cognitive impairment in patients with secondary progressive multiple sclerosis, and also outlines the knowledge gaps (4:16).

Laurent Servais reports on part 1 of the FIREFISH trial of risdiplam in infants with type 1 spinal muscular atrophy showing improvements in various outcomes, including motor function and ventilation (3:55).

Tatyana Simuni describes the clinical and imaging features of LRRK2 and GBA mutation carriers participating in the Parkinson's Progression Markers Initiative cohort (6:29).

Jordi Matias-Guiu summarises the findings of their prospective study investigating the use of amyloid positron emission tomography to identify multiple sclerosis patients likely to experience cognitive impairment (3:10).

Thomas Leist takes us through the 1-year interim analysis of the CHORDS study of ocrelizumab comprising multiple sclerosis patients drawn from community practice (2:04).

Enrique Alvarez discusses their research demonstrating a difference in the efficacy of multiple sclerosis medications by age, and comments on the implications for clinical practice (5:04).

Thomas Leist outlines a post-hoc analysis of the ORACLE-MS trial of individuals with a first demyelinating event showing that all subgroups appear to benefit from treatment with cladribine. He also discusses future directions of research (3:52).

Jeremy Chataway reports on the latest findings from the MS-SMART trial that evaluated the efficacy of amiloride, fluoxetine and riluzole versus placebo in reducing disability in progressive multiple sclerosis as a way of speeding up phase II trial activity (2:57).

Jerry Wolinksy summarises his findings from the open-label extension period of the phase III ORATORIO trial looking at sustained disability progression with ocrelizumab in patients with primary progressive multiple sclerosis (8:20).

Roos M van der Vuurst de Vries discusses her McDonald 2017 criteria findings, which provide further support of improved sensitivity for diagnosing clinically definite multiple sclerosis in patients with clinically isolated syndrome (5:05).

Wallace Brownlee presents his study showing that the revised McDonald 2017 criteria are more sensitive than the McDonald 2010 criteria, albeit with a modest reduction in specificity, for diagnosing multiple sclerosis in patients with typical clinically isolated syndrome characteristics (3:49).

Pietro Iaffaldano shares his real-world findings from the Big Multiple Sclerosis Data Network showing an optimal time to treatment initiation of 6 months in patients with relapsing-remitting multiple sclerosis (1:51).

Wallace Brownlee talks about his group’s findings that conventional MRI measures of inflammatory disease could help identify patients with early multiple sclerosis who are at high risk of developing cognitive disability (3:05).

Antonio Scalfari gives an overview of findings showing that early focal cortical lesions at multiple sclerosis onset is associated with earlier relapse and an increased risk of converting to secondary progressive multiple sclerosis (4:14).  

Tim Spelman discusses his team’s findings of a significant reduction in relapse rates and greater disability improvement in multiple sclerosis patients who relapse on first-line treatment and switch to natalizumab versus fingolimod (2:55).

Nathaniel Lizak presents study findings showing that ongoing relapse in patients with multiple sclerosis is not a contraindication to disease-modifying treatment (2:19).